Tumour Cell Secretome in Chemoresistance and Tumour Recurrence
- PMID: 32460003
- DOI: 10.1016/j.trecan.2020.02.020
Tumour Cell Secretome in Chemoresistance and Tumour Recurrence
Abstract
Chemoresistance is a major factor driving tumour relapse and the high rates of cancer-related deaths. Understanding how cancer cells overcome chemotherapy-induced cell death is critical in promoting patient survival. One emerging mechanism of chemoresistance is the tumour cell secretome (TCS), an array of protumorigenic factors released by tumour cells. Chemotherapy exposure can also alter the composition of the TCS, known as therapy-induced TCS, and can promote tumour relapse and the formation of an immunosuppressive tumour microenvironment (TME). Here, we outline how the TCS can protect cancer cells from chemotherapy-induced cell death. We also highlight recent evidence describing how therapy-induced TCS can impact cancer stem cell (CSC) expansion and tumour-associated immune cells to enable tumour regrowth and antitumour immunity.
Keywords: cancer stem cells (CSCs); chemoresistance; immune escape, tumour cell secretome (TCS); tumour microenvironment (TME); tumour relapse.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells.Semin Cancer Biol. 2018 Dec;53:265-281. doi: 10.1016/j.semcancer.2018.10.002. Epub 2018 Oct 11. Semin Cancer Biol. 2018. PMID: 30317036 Review.
-
The Role of the Microenvironment and Immune System in Regulating Stem Cell Fate in Cancer.Trends Cancer. 2021 Jul;7(7):624-634. doi: 10.1016/j.trecan.2020.12.014. Epub 2021 Jan 26. Trends Cancer. 2021. PMID: 33509688 Free PMC article. Review.
-
Cancer Stem Cells and Targeting Strategies.Cells. 2019 Aug 18;8(8):926. doi: 10.3390/cells8080926. Cells. 2019. PMID: 31426611 Free PMC article. Review.
-
Gap Junctions and Breast Cancer Dormancy.Trends Cancer. 2020 Apr;6(4):348-357. doi: 10.1016/j.trecan.2020.01.013. Epub 2020 Feb 20. Trends Cancer. 2020. PMID: 32209448 Review.
-
Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update.Nat Rev Clin Oncol. 2020 Apr;17(4):204-232. doi: 10.1038/s41571-019-0293-2. Epub 2019 Dec 2. Nat Rev Clin Oncol. 2020. PMID: 31792354 Review.
Cited by
-
Targeting of BCL-2 Family Members during Anticancer Treatment: A Necessary Compromise between Individual Cell and Ecosystemic Responses?Biomolecules. 2020 Jul 25;10(8):1109. doi: 10.3390/biom10081109. Biomolecules. 2020. PMID: 32722518 Free PMC article. Review.
-
Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer.Cell Death Dis. 2023 May 5;14(5):306. doi: 10.1038/s41419-023-05806-z. Cell Death Dis. 2023. PMID: 37142595 Free PMC article.
-
Cancer-Associated Fibroblasts: Implications for Cancer Therapy.Cancers (Basel). 2021 Jul 14;13(14):3526. doi: 10.3390/cancers13143526. Cancers (Basel). 2021. PMID: 34298736 Free PMC article. Review.
-
A Novel Dialkylamino-Functionalized Chalcone, DML6, Inhibits Cervical Cancer Cell Proliferation, In Vitro, via Induction of Oxidative Stress, Intrinsic Apoptosis and Mitotic Catastrophe.Molecules. 2021 Jul 11;26(14):4214. doi: 10.3390/molecules26144214. Molecules. 2021. PMID: 34299490 Free PMC article.
-
Intratumoral Heterogeneity in Lung Cancer.Cancers (Basel). 2023 May 11;15(10):2709. doi: 10.3390/cancers15102709. Cancers (Basel). 2023. PMID: 37345046 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
